Brown, D, Larkin, F, Sengupta, S, Romero-Ureclay, JL, Ross, CC, Gupta, N, Das, M. Clozapine: an effective treatment for seriously violent and psychopathic men with antisocial personality disorder in a UK high-security hospital. CNS Spectr. 2014; 19(5): 391–402.
Larkin, E, Murtagh, S, Jones, S. A preliminary study of violent incidents in a special hospital (Rampton). Br J Psychiatry. 1988; 153(2): 226–231.
Gordon, H, Grubin, D. Psychiatric aspects of the assessment and treatment of sex offenders. Advances in Psychiatric Treatment. 2004; 10(1): 73–80.
Rutherford, M, Duggan, S. Forensic mental health services: facts and figures on current provision. British Journal of Forensic Practice. 2008; 10(4): 4–10.
Blackburn, R, Logan, C, Donnelly, J, Renwick, S. Personality disorders, psychopathy and other mental disorders: co-morbidity among patients at English and Scottish high-security hospitals. Journal of Forensic Psychiatry & Psychology. 2003; 14(1): 111–137.
Thomas, S, Leese, M, Dolan, M, et al. The individual needs of patients in high secure psychiatric hospitals in England. Journal of Forensic Psychiatry & Psychology. 2004; 15(2): 222–243.
Stone, JH, Roberts, M, O’Grady, J, Taylor, AV, O’ Shea, K.
Faulk’s Basic Forensic Psychiatry. Hoboken, NJ: Wiley; 1999.
Department of Health. Mental Health Act. London; 1983 rev. 2007; HMSO.
Hayhurst, K. Pennine Care NHS Trust Antipsychotic Prescribing Audit. Manchester, UK: The University of Manchester; 2006.
Harrington, M, Lelliott, P, Paton, C, Okocha, C, Duffett, R, Sensky, T. The results of a multi-centre audit of the prescribing of antipsychotic drugs for in-patients in the UK. Psychiatric Bulletin. 2002; 26(11): 414–418.
Stahl, SM. “The metabolic syndrome”: psychopharmacologists should weigh the evidence for weighing the patient. J Clin Psychiatry. 2002; 63(12): 1094–1095.
Gupta, A, Dadheech, G, Yadav, D, Sharma, P, Gautam, S. Metabolic issues in schizophrenic patients receiving antipsychotic treatment. Indian J Clin Biochem. 2014; 29(2): 196–201.
Ojala, K, Niskanen, L, Tiihonen, J, Paavola, P, Putkonen, A, Repo-Tiihonen, E. Characterization of metabolic syndrome among forensic psychiatric inpatients. Journal of Forensic Psychiatry & Psychology. 2008; 19(1): 33–51.
Taylor, PJ, Leese, M, Williams, D, Butwell, M, Daly, R, Larkin, E. Mental disorder and violence: a special (high security) hospital study. Br J Psychiatry. 1998; 172(3): 218–226.
British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary. London: BMJ Books & Pharmaceutical Press; 2015.
Stahl, SM. Antipsychotic polypharmacy: never say never, but never say always. Acta Psychiatr Scand. 2012; 125(5): 349–351.
Stahl, SM. Emerging guidelines for the use of antipsychotic polypharmacy. Rev Psiquiatr Salud Ment. 2013; 6(3): 97–100.
Stahl, SM. Antipsychotic polypharmacy: squandering precious resources?
J Clin Psychiatry. 2002; 63(2): 93–94.
Adams, CE, Fenton, MK, Quraishi, S, David, AS. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry. 2001; 179(4): 290–299.
Barnes, TR, Shingleton-Smith, A, Paton, C. Antipsychotic long-acting injections: prescribing practice in the UK. Br J Psychiatry. 2009; 195(52): S37–S42.
Gibbon, S, Silva, E, Kaler, R, et al. Risperidone long-acting injection (RLAI)—real world outcomes from the United Kingdom high-secure hospitals. The British Journal of Forensic Practice. 2011; 13(4): 264–269.
Baruch, N, Das, M, Sharda, A, et al. An evaluation of the use of olanzapine pamoate depot injection in seriously violent men with schizophrenia in a UK high-security hospital. Ther Adv Psychopharmacol. 2014; 4(5): 186–192.
Walsh, E, Leese, M, Taylor, P, et al. Psychosis in high-security and general psychiatric services Report from the UK700 and Special Hospitals’ Treatment Resistant Schizophrenia groups. Br J Psychiatry. 2002; 180(4): 351–357.
Frogley, C, Taylor, D, Dickens, G, Picchioni, M. A systematic review of the evidence of clozapine’s anti-aggressive effects. Int J Neuropsychopharmacol. 2012; 15(9): 1351–1371.
Das, M, Barkataki, I, Kumari, V, Sharma, T. Neuroimaging violence in the mentally ill: what can it tell us?
Hosp Med. 2002; 63(10): 604–609.
Kumari, V, Das, M, Hodgins, S. Association between violent behaviour and impaired prepulse inhibition of the startle response in antisocial personality disorder and schizophrenia. Behav Brain Res. 2005; 158(1): 159–166.
Kumari, V, Soni, W, Sharma, T. Normalization of information processing deficits in schizophrenia with clozapine. Am J Psychiatry. 1999; 156(7): 1046–1051.
Stahl, SM. Clozapine: is now the time for more clinicians to adopt this orphan?
CNS Spectr. 2014; 19(4): 279–281.
Raedler, TJ. Cardiovascular aspects of antipsychotics. Curr Opin Psychiatry. 2010; 23(6): 574–581.
Brown, D, Larkin, F, Sengupta, S, et al. Treatment of violent dissocial personality disorder patients with clozapine requires lower dose and therapeutic levels than in schizophrenia. Schizophrenia Research. 2014; 153(Suppl 1): S173.
Young, SL, Taylor, M, Lawrie, SM. “First do no harm”: a systematic review of the prevalence and management of antipsychotic adverse effects. J Psychopharmacol. 2015; 29(4): 353–362.
Hotham, JE, Simpson, PJ, Brooman-White, RS, et al. Augmentation of clozapine with amisulpride: an effective therapeutic strategy for violent treatment-resistant schizophrenia patients in a UK high-security hospital. CNS Spectr. 2014; 19(5): 403–410.
Genç, Y, Taner, E, Candansayar, S. Comparison of clozapine-amisulpride and clozapine-quetiapine combinations for patients with schizophrenia who are partially responsive to clozapine: a single-blind randomized study. Adv Ther. 2007; 24(1): 1–13.
Cipriani, A, Boso, M, Barbui, C. Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. Cochrane Database Syst Rev. 2009;■(3): CD006324.
Suzuki, T, Uchida, H, Takeuchi, H, et al. Augmentation of atypical antipsychotics with valproic acid: an open‐label study for most difficult patients with schizophrenia. Hum Psychopharmacol. 2009; 24(8): 628–638.
Ho, DK, Kottalgi, G, Ross, CC, Romero-Ulceray, J, Das, M. Treatment with triptorelin in mentally disordered sex offenders: experience from a maximum-security hospital. J Clin Psychopharmacol. 2012; 32(5): 739–740.
Zachariah, E, Kumari, V, Galea, A, et al. Effects of oral procyclidine administration on cognitive functions in healthy subjects: implications for schizophrenia. J Clin Psychopharmacol. 2002; 22(2): 224–226.
Ingenhoven, T, Lafay, P, Rinne, T, et al. Effectiveness of pharmacotherapy for severe personality disorders: meta-analyses of randomized controlled trials. J Clin Psychiatry. 2010; 71(1): 14–25.
Stahl, SM, Morrissette, DA, Cummings, M, et al. California State Hospital Violence Assessment and Treatment (Cal-VAT) guidelines. CNS Spectr. 2014; 19(5): 449–465.